Silicon Valley Professionals are Taking LSD at Work to Increase Productivity

lsd

An increasing number of twenty-somethings are reportedly ‘micro-dosing’ on psychedelic drugs – and they say it’s making them better workers.

Could taking LSD at work make your more productive?

“You’re doing a task you normally couldn’t stand for two hours, but you do it for three or four. You eat properly. Maybe you do one more set of reps. Just a good day. That seems to be what we’re discovering.”

— Dr James Fadiman, psychedelics researcher

Adam Boult reports: It seems unlikely, but that’s apparently what some Silicon Valley professionals have been doing – and reporting great results.

According to Rolling Stone, a growing number of people are experimenting with “microdoses” of psychedelics to help them work.

A microdose of LSD is around 10-15 micrograms, approximately a tenth of a “normal” dose.

lsd-rs

“You’re doing a task you normally couldn’t stand for two hours, but you do it for three or four. You eat properly. Maybe you do one more set of reps. Just a good day. That seems to be what we’re discovering.”

At that dosage, Rolling Stone describes the drug’s effects as “subperceptual”: ” ‘Enough, says Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies, ‘to feel a little bit of energy lift, a little bit of insight, but not so much that you are tripping.’”

Psychedelics researcher Dr James Fadiman discussed microdosing with Vice, saying: ‘People do it and they’re eating better, sleeping better, they’re often returning to exercise or yoga or meditation. It’s as if messages are passing through their body more easily.”

• LSD popular again, expert warns 

• Oliver Sacks’ most mind-bending experiment

“But what many people are reporting is, at the end of the day, they say, ‘That was a really good day.’ You know, that kind of day when things kind of work.” Read the rest of this entry »


Psychedelics: Ready for a Medical Comeback 

BOOKS-ACIDTEST

In Switzerland, Canada, Brazil, Peru, Mexico and the United States, researchers with no evident countercultural tendencies are conducting research that is finding psychedelic drugs a valuable adjunct to psychotherapy in treating addiction, post-traumatic stress and the depression or anxiety that often comes with terminal illness.

Melissa Healy reports: New research on the use of psychedelic drugs as treatment for a range of mental disorders appears to be throwing open doors of perception long closed within the medical community, says a new analysis in the Canadian Medical Assn. Journal.

“Experimental therapeutic uses of psychedelic drugs have been tightly controlled, requiring extensive screening of prospective patients, close monitoring during medication use, and extended follow-up.”

For several decades, the North American medical establishment has classified psychedelic drugs — including lysergic acid diethylamide (LSD), psilocybin and methylenedioxymethamphetamine (MDMA) — as drugs of abuse with little to no medical purpose or means of safe use.

LSDTrippinFamily

“But for all of that, when psychedelics such as MDMA have been tested in conjunction with psychotherapy for PTSD, or psilocybin for alcohol dependence, ‘relatively time-limited interventions’ have been shown to have enduring benefits.”

That, four researchers argue, is changing.

[Also see – LSD, Reconsidered for Therapy]

[More – Psychedelics: Poised for a Comeback]

In Switzerland, Canada, Brazil, Peru, Mexico and the United States, researchers with no evident countercultural tendencies are conducting research that is finding psychedelic drugs a valuable adjunct to psychotherapy in treating addiction, post-traumatic stress and the depression or anxiety that often comes with terminal illness.

Hoffman-LSD-img

“It’s been a cautious road, but one that’s data-driven. A big factor is really that enough time has passed for the sensationalism to kind of simmer down and for sober heads to say, ‘Hold on, let’s look at the evidence.'”

While most are small-scale pilot studies, larger trials are planned — and “more and more people are becoming interested and even jumping into the field to start trials themselves,” said senior author Matthew W. Johnson, a professor of psychiatry and behavioral sciences at Johns Hopkins University. Read the rest of this entry »